A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ziopharm
• Treatments: Ifosfamide; Isophosphamide mustard

Criteria

Inclusion Criteria:

• Metastatic and /or unresectable disease state after previous standard chemotherapy